Mitigating the risk: manufacturing high potency drugs

06 June 2018
By ChargePoint Technology

A growing demand for highly potent active pharmaceutical ingredients (HPAPIs), twinned with the prevalence of oncological, immunosuppressant and hormone-based products is fuelling need for high potency handling capabilities. 

ChargePoint Technology's very own Michael Avraam discusses the potential issues with containment performance testing, data collection and interpretation and how these may affect end user with Pharma Focus Asia. You can read the full article (pg.50) here

Leave a Comment

Name
Email
Comment